Executive Summary
Overview of the report
Study Methodology
Section I:
Background on Antibody–Drug Conjugates
-
In the era precision medicine
-
Bio engineering breakthrough
-
New emergence of ADCs as cancer treatments
-
Increasing number of cancer patients and longer life expectancy
-
High needs in non-invasive treatment
Section II:
ADCs Market Overview
-
1. ADCs Market Growth and Projection
-
-
Fast-expanding therapeutic modality
-
-
Unique therapeutic value of ADCs
-
-
Accelerated penetration of big pharma into ADCs
-
2. Market opportunities and challenges
-
3. Approval and development Overview
-
-
Approval and regulatory landscape
-
-
Preclinical
-
-
Phase l
-
-
Phase ll
-
-
Phase lll
-
4. Market Segmentation by disease application
-
-
Oncological indication
-
-
Hematological indication
-
-
Non oncological (autoimmune and infectious disease)
Section lll:
ADCs CDMO Market Outlook
-
Market Overview
-
Growth drivers and projections
-
Opportunities and challenges
Section IV:
ADC Manufacturing Technologies
-
Three important components of ADCs
-
Comparison of different ADCs manufacturing technologies
-
-
Cleavable and non-cleavable
-
-
Linker technology
-
-
Linkerless ADCs
-
Analysis on payload technology
Section V:
Unique Considerations and Complexities in ACD Development and Manufacturing
-
Overview of the unique considerations and complexities in ADC development and manufacturing
-
Challenges in developing and manufacturing ADCs
-
Impact of these challenges on the development and manufacturing process
Section VI:
Strategic Pricing Study
-
Manufacturing process
-
Strategic pricing
Section VII:
ADCs CDMOs Profile
-
Regional Analysis
-
Summary of Services and capacities
-
Individual company profiles